Effects Of Bauhinia Bauhinioides Kallikrein Proteinase Inhibitor In Mice With Asthma-Copd

Background: Asthma and chronic obstructive pulmonary disease (COPD) are major public health problems. There is a significant proportion of patients with asthma associated with COPD. Plant-derived Bauhinia bauhinioides Kallikrein Proteinase inhibitor (BbKI) has potent anti-inflammatory and anti-oxidant effects and can be a potential new therapeutic treatment to control lung diseases. Objective: To investigate the mechanisms involved in the effect of BbKI treatment in a model of asthma associated with COPD (OVA+ELA). Methods: Male Balb/c mice were divided into groups (n=8): SAL, OVA, ELA, OVA+ELA and OVA+ELA-BbKI. We evaluated: exhaled nitric oxide (eNO), resistance (Rrs) and elastance (Ers) of respiratory system and bronchoalveolar lavage fluid (BALF) cells. We considered the maximum increase of %Rrs and %Ers and p<0.05 was considered significant. Results: There was an increase in %Rrs and BALF total cells in OVA+ELA compared to OVA and ELA (p<0.05). We observed a decrease in %Ers in ELA and OVA+ELA compared to OVA (p<0.05). We did not observe any difference in %Ers in ELA and OVA+ELA. The eNO of OVA+ELA-BbKI(9.8±3.4ppb) decreased compared to OVA+ELA(41.0±5.1ppb, p<0.05). The %Rrs was attenuated in OVA+ELA-BbKI(260.7±31.5%) compared to OVA+ELA(625.15±81.05%). The %Ers of OVA+ELA-BbKI(110.3±28.8%) increased compared to OVA+ELA(36.43±4.8%, p<0.05). Considering BALF total cells, OVA+ELA-BbKI (9.4±2.2 x104cells/mL) decreased compared to OVA+ELA(23.2±2.9x104cells/mL, p<0.05). Conclusion: BbKI treatment reduces lung mechanical and inflammatory alterations of experimental model of asthma associated to COPD. Financial Support: FAPESP (number2018/02537-5), CNPq, LIM-20-HC-FMUSP.